Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor

NCT07166315 is registered in ClinicalTrials.gov with Adelphi Real World as lead sponsor.

NCT NCT07166315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07166315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
Lead sponsor
Adelphi Real World
Phase
Observational
Overall status
Recruiting
Start date
July 7, 2025
Completion date
March 31, 2027
Enrollment
700 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondylarthritis (axspa), psoriatic arthritis (psa)